Minimal change disease cost-effectiveness of therapy

	Minimal Change Disease Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Minimal Change Disease from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Immunohistology
Electron Microscopy
Electrocardiogram
X-ray
Echocardiorgaphy or Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Minimal change disease cost-effectiveness of therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Minimal change disease cost-effectiveness of therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Minimal change disease cost-effectiveness of therapy
CDC on Minimal change disease cost-effectiveness of therapy
Minimal change disease cost-effectiveness of therapy in the news
Blogs on Minimal change disease cost-effectiveness of therapy
Directions to Hospitals Treating Minimal change disease
Risk calculators and risk factors for Minimal change disease cost-effectiveness of therapy

Overview

Azathioprine may be cost effective in treating the patients with minimal change disease .

Azathioprine therapy may used in glucocorticoid-resistant disease with the patients of minimal change disease.^[1]
Azathioprine is cost effective and may be as effective and less costly than MMF for this indication.

↑ Nolasco F, Cameron JS, Heywood EF, Hicks J, Ogg C, Williams DG (June 1986). "Adult-onset minimal change nephrotic syndrome: a long-term follow-up". Kidney Int. 29 (6): 1215–23. PMID 3747335.